m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer

Jun Liu,Mark A. Eckert,Bryan T. Harada,Song-Mei Liu,Zhike Lu,Kangkang Yu,Samantha M. Tienda,Agnieszka Chryplewicz,Allen C. Zhu,Ying Yang,Jing-Tao Huang,Shao-Min Chen,Zhi-Gao Xu,Xiao-Hua Leng,Xue-Chen Yu,Jie Cao,Zezhou Zhang,Jianzhao Liu,Ernst Lengyel,Chuan He
DOI: https://doi.org/10.1038/s41556-018-0174-4
IF: 21.3
2018-08-27
Nature Cell Biology
Abstract:N6-methyladenosine (m6A) messenger RNA methylation is a gene regulatory mechanism affecting cell differentiation and proliferation in development and cancer. To study the roles of m6A mRNA methylation in cell proliferation and tumorigenicity, we investigated human endometrial cancer in which a hotspot R298P mutation is present in a key component of the methyltransferase complex (METTL14). We found that about 70% of endometrial tumours exhibit reductions in m6A methylation that are probably due to either this METTL14 mutation or reduced expression of METTL3, another component of the methyltransferase complex. These changes lead to increased proliferation and tumorigenicity of endometrial cancer cells, likely through activation of the AKT pathway. Reductions in m6A methylation lead to decreased expression of the negative AKT regulator PHLPP2 and increased expression of the positive AKT regulator mTORC2. Together, these results reveal reduced m6A mRNA methylation as an oncogenic mechanism in endometrial cancer and identify m6A methylation as a regulator of AKT signalling.
cell biology
What problem does this paper attempt to address?